Prospective comparison of mirabegron and fesoterodine for overactive bladder
Not Applicable
- Conditions
- Overactive bladder(OAB)
- Registration Number
- JPRN-UMIN000045947
- Lead Sponsor
- agasaki University Hospital Department of urology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 140
Inclusion Criteria
Not provided
Exclusion Criteria
Patients were excluded if they received treatment with anticholinergic agents,beta3-adrenoceptor agonist,BOTOX injection,propafenone hydrochloride or flecainide acetate; if they had hypersensitivity to mirabegron,fesoterodine or tolterodine; if they had renal dysfunction,hepatic dysfunction,severe cardiac disease,urinary retention,closed-angle glaucoma,ileus,atony or myasthenia gravis; if they are not able to answer questionnaires and they need proxies; if they are pregnant or want to have a baby in the future; and if they pacitipated other clinical research.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Improvement of 3 points or more in total OABSS(OAB symptom scores) after 12 weeks' treatment
- Secondary Outcome Measures
Name Time Method ess than 1 point in OABSS-Q3 or less than 2 ponits in total OABSS score after 12 weeks' treatment